focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,795.00
Bid: 1,795.00
Ask: 1,795.50
Change: -17.50 (-0.97%)
Spread: 0.50 (0.028%)
Open: 1,792.50
High: 1,802.00
Low: 1,792.50
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Shares Seen Higher; Sky Hikes Dividend

Wed, 29th Jul 2015 06:34

LONDON (Alliance News) - London stocks are set to open higher Wednesday, following a flurry of UK company updates, with broadcaster Sky increasing its full year dividend as it posted a rise in pretax profit.

Sky posted a pretax profit of GBP1.52 billion for the year to end-June, up from GBP1.03 billion a year before, as revenue rose to GBP9.99 billion from GBP7.45 billion. The reported results include Sky Italia and Sky Deutschland following their acquisition in November. On an adjusted basis, including the results of the Italian and German business for the full year and at constant currency, pretax profit rose to GBP1.20 billion, up from GBP1.13 billion a year before, on revenue of GBP11.28 billion, up from GBP10.78 billion.

The company proposed a final dividend of 20.5 pence, which takes its total dividend for the year to 32.8 pence, up from 32.0 pence a year before.

There also have been results from Barclays, Taylor Wimpey and Capita, among others. GlaxoSmithKline is expected to release its second-quarter results at 1200 BST.

In its first set of results since the board sacked Antony Jenkins as chief executive earlier this month, Barclays reported an increase in second-quarter net profit, and revealed plans to intensify the scaling down of its non-core assets.

Net profit increased to GBP1.15 billion in the quarter ended June 30, compared with GBP161 million in the corresponding period the prior year. Adjusted pretax profit, a closely watched measure of the bank's performance, increased to GBP1.85 billion in the quarter, up from GBP1.66 billion year-on-year, ahead of the GBP1.75 billion forecast by analysts.

Barclays's interim dividend remains at 2.0 pence per share.

IG says futures indicate the FTSE 100 to open 28 points higher at 6,583.30. The index closed up 0.8% at 6,555.28, taking back about half of Monday's losses.

Later in the day, attention will shift to the US Federal Open Market Committee two-day meeting, with its interest rate announcement due at 1900 BST. Ahead of the decision, Wall Street ended higher Tuesday. The DJIA closed up 1.1%, the S&P 500 ended up 1.2% and the Nasdaq Composite finished up 1.0%.

The US Federal Reserve is widely expected to leave US interest rates unchanged at the meeting. However, investors will pay attention to the accompanying monetary policy statement, after a recent hawkish speech and Congressional testimony by Fed Chair Janet Yellen intensified expectations that the bank would hike rates later this year.

Many analysts still expect the Fed to raise US interest rates at its next meeting in September and will be closely scrutinizing the statement for any hints about the timing of the first US rate hike in nine years.

Lloyds Bank highlights that the bigger question is whether the Fed wants to send a clearer signal that it intends to hike at its next meeting in September. The bank notes that at the start of the previous interest rate tightening cycle in 2004, the statement was changed to read "the Committee believes that policy accommodation can be removed at a pace that is likely to be measured".

"A similar change in language this time would strongly suggest that the FOMC intends to hike at the next meeting, unless the economic data take a decisive turn for the worse," says Lloyds.

CMC Markets chief market analyst Michael Hewson says, "a lot can happen, not only data wise between now and [when a rate hike arrives], but there also remains a great deal of uncertainty between now and then with respect to the China growth story, as well as a successful outcome to what is currently going in Greece."

Greece's government launched negotiations Tuesday on a new multi-billion-euro bailout programme, insisting that it has taken all the measures agreed with creditors for reaching a deal. Representatives of Greece's creditors started talks at a technical level, visiting Greece's General Accounting Office and the Bank of Greece, a Greek finance ministry official said Tuesday.

The same official said "technical groups are expected to complete their work by Friday 31 July" adding that no further meetings are expected during the weekend, "unless otherwise specified".

According to the same official, mission chiefs of the institutions overseeing the bailout - the European Commission, the European Central Bank, the International Monetary Fund as well as the European Stability Mechanism are expected to arrive in Athens on Wednesday. The official said both sides aim to complete the deal "as soon as possible."

The Greek Parliament passed two reform packages that were part of the conditions agreed on July 13 in Brussels to secure up to EUR86 billion in new financing. The major sticking point is whether Greece will have to pass another round of difficult and politically divisive austerity measures, such as pension reforms, before negotiations conclude.

In Asia on Wednesday, the Japanese Nikkei 225 closed down 0.2%. In China, stocks are mixed, with the Hang Seng up 0.2%, and the Shanghai Composite down 0.2%.

Alongside the Fed interest rate decision, in the economic calendar are UK consumer credit and mortgage approvals data due at 0930 BST. In the US, pending home sales are due at 1500 BST, while EIA Crude Oil stocks are at 1530 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:45

Citi ups recommendation on GSK to 'buy'

(Sharecast News) - Citi has upgraded its rating on vaccines and drugs blue chip GSK to 'buy' while also boosting its earnings estimates.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
13 Feb 2024 07:45

LONDON BRIEFING: "Record" Tui quarter; Ultimate Products eyes payouts

(Alliance News) - London's FTSE 100 is to open ever-so-slightly lower on Tuesday, with trade set to be nervy ahead of the afternoon's US inflation data.

Read more
12 Feb 2024 17:11

London close: Stocks finish higher after very quiet Monday

(Sharecast News) - London markets managed modest gains by the close of a subdued trading session on Monday, with no significant corporate or economic catalysts driving movements.

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.